EMA and national agencies outline their vision of the future regulatory network
This article was originally published in Scrip
EU regulators have sketched out the future challenges facing the European regulatory network and its stakeholders over the coming five years and more, and have come up with solutions aimed at allowing innovation to be fostered while protecting public health and pursuing greater global collaboration and the wider adoption of common standards.
You may also be interested in...
The US company is bringing extra supplies of lopinavir/ritonavir into France but stresses that the combination treatment is not authorized for treating patients with the coronavirus.
As part of its efforts to preserve patient access to medicines amid the COVID-19 pandemic, Russia is planning to cap drug prices if increases of more than 30% are detected. It will also allow online sales of non-prescription drugs and may also tighten the rules on fake and substandard products.
France is exploring the use of hydroxychloroquine and lopinavir/ritonavir in COVID-19, but only in hospitalized patients and in clinical trials, and has banned all exports of the products to avoid possible shortages.